| 1 |
NCT02810678 |
Recruiting |
Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment |
- Latent Tuberculosis Infection
|
- Other: Latent Tuberculosis Infection program evaluation & diagnosis
|
Interventional
|
Not Applicable |
- McGill University
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The primary outcome will be the change in the number of household contacts (HHC) initiating treatment per newly diagnosed TB index patient within 3- 4 months from index patient diagnosis, between Phase 1 and Phase 2
- Health system costs related to the implementation of the LTBI program evaluation and strengthening approach
- Cross-over
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT02810678 |
FND-143350 |
ACT4 |
July 2016 |
December 2018 |
April 2019 |
June 23, 2016 |
September 7, 2018 |
|
- Centre de Pneumo-Phthysiologie
Cotonou, Benin - University of Calgary
Calgary, Alberta, Canada - University of Alberta
Edmonton, Alberta, Canada - (and 5 more...)
|
|
| 2 |
NCT02910557 |
Recruiting |
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection |
- Melanoma
- Herpetic Infection
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence Rate
- Herpectic Infection with T-VEC for Close Contacts and HCPs
- Incidence of Herpetic Infection with TVEC in Patients during treatment
- (and 7 more...)
|
920 |
All |
Child, Adult, Older Adult |
NCT02910557 |
20130193 |
|
August 10, 2017 |
August 28, 2024 |
August 28, 2024 |
September 22, 2016 |
February 8, 2019 |
|
- Research Site
Jefferson City, Missouri, United States - Research Site
Cincinnati, Ohio, United States - Research Site
Pittsburgh, Pennsylvania, United States - (and 12 more...)
|
|
| 3 |
NCT02467439 |
Recruiting |
Acute Partner and Social Contact Referral: iKnow |
- Acute HIV Infection
- HIV Seropositive
- Sexually Transmitted Infections
|
- Other: Notification cards
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- the proportion of HIV-seropositive index participants with at least one newly diagnosed HIV-infected partner or social contact
- The proportion of HIV-seropositive index participants with at least one HIV-infected person referred who is not in care (newly diagnosed plus known diagnoses not in care)
- Total HIV-infected persons, including all subsequent referrals, referred per first-wave index
- (and 2 more...)
|
5975 |
All |
18 Years and older (Adult, Older Adult) |
NCT02467439 |
14-2869
UNCPM 21414
1R01AI114320-01 |
|
June 2015 |
October 2019 |
June 2020 |
June 10, 2015 |
February 1, 2019 |
|
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 4 |
NCT02581579 |
Recruiting |
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection |
|
- Dietary Supplement: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Other: Placebo
|
Interventional
|
Not Applicable |
- Manresana de Micobacteriologia, SL
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from Baseline in Specific Treg memory cells at week 1
- Proportion of patients presenting adverse events related to study treatment.
- Proportion of participants presenting gastrointestinal adverse events related to study treatment.
- Proportion of participants presenting systemic adverse events related to study treatment.
|
24 |
All |
2 Years to 17 Years (Child) |
NCT02581579 |
NYADAPETRICS |
|
November 2015 |
December 28, 2018 |
December 28, 2018 |
October 21, 2015 |
October 31, 2018 |
|
- Germans Trias I Pujol Hospital
Badalona, Barcelona, Spain - Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona, Spain - Valle Hebron Hospital
Barcelona, Spain
|
|
| 5 |
NCT03778164 |
Not yet recruiting |
Improving Prevention Systems to Reduce Disparities for High Priority Populations |
|
- Other: Fast Track Partner Services-Sexual Health Intervention
- Other: Partner Services Standard of Care
|
Interventional
|
Not Applicable |
- Hunter College of City University of New York
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Acceptance of HIV Testing
- PrEP/ARV Initiation
- Linkage to PrEP/HIV Care
- STI testing
|
1150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03778164 |
R01MH115835 |
FastTrack |
January 2020 |
June 2022 |
September 2022 |
December 18, 2018 |
December 19, 2018 |
|
|
|
| 6 |
NCT03250104 |
Recruiting |
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives |
- Clostridium Difficile Infection
- VRE Infection
- Nosocomial Infection
- MRGN Bacteria
|
- Other: Infection Control
- Other: Antibiotic Stewardship
|
Observational
|
|
- University Hospital of Cologne
- Charite University, Berlin, Germany
- University Hospital Freiburg
- (and 3 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- CDI incidence
- Effectiveness of IC bundle through incidence of CDI or BSI by VRE and MRGN
- PPI usage
- (and 4 more...)
|
80000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03250104 |
TTU HAARBI 8.810 |
ABSOLUTE |
November 2016 |
December 2018 |
December 2020 |
August 15, 2017 |
October 16, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
|
| 7 |
NCT00796146 |
Recruiting |
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population |
|
|
Observational
|
|
- South East Asia Research Collaboration with Hawaii
- Armed Forces Research Institute of Medical Sciences, Thailand
- Thai Red Cross AIDS Research Centre
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of HIV and non-HIV related clinical events
- demographics and behavioral risk factors for those identified with acute HIV infection
- neurocognitive function and neuroimaging findings in acute HIV infection as well as describe immune response, HIV-1 genotypes and sequences in the cerebrospinal fluid
- (and 4 more...)
|
536 |
All |
18 Years and older (Adult, Older Adult) |
NCT00796146 |
SEARCH010/ RV 254 |
|
April 2009 |
April 2019 |
July 2019 |
November 24, 2008 |
April 18, 2018 |
|
- Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
|
| 8 |
NCT02572791 |
Recruiting |
Staph Household Intervention for Eradication (SHINE) |
- Skin and Subcutaneous Tissue Bacterial Infections
- Staphylococcus Aureus
- MRSA - Methicillin Resistant Staphylococcus Aureus Infection
|
- Drug: Chlorhexidine
- Drug: Mupirocin
- Behavioral: Household cleaning
|
Interventional
|
Phase 4 |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of SSTI
- Prevalence of S. aureus colonization in index patients, household contacts, pet dogs and cats, and household surfaces
- Confirmed S. aureus Infection
- (and 4 more...)
|
207 |
All |
up to 18 Years (Child, Adult) |
NCT02572791 |
3177 60559 |
SHINE |
October 2015 |
January 2020 |
July 2020 |
October 9, 2015 |
March 20, 2018 |
|
- St. Louis Children's Hospital
Saint Louis, Missouri, United States - Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 9 |
NCT02819232 |
Recruiting |
Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs |
|
|
Interventional
|
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.
|
864 |
All |
18 Years and older (Adult, Older Adult) |
NCT02819232 |
2012-40
2012-A01568-35 |
Keratite |
March 2013 |
March 2019 |
September 2019 |
June 30, 2016 |
June 30, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
|
| 10 |
NCT02653404 |
Recruiting |
IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection |
- Tuberculosis, Pulmonary
- Interferon-gamma Release Tests
- Tuberculin Test
|
- Other: IGRA test (QTF-GIT)
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Other
|
- Number of patients with concordance of QTF-GIT test and TST,among children exposed to TB
- Number of patients with positivity of QTF-GIT in comparison with TST among children with active tuberculosis disease
- Number of patients with a negative QTF-GIT test in comparison of TST, among non-infected children
|
50 |
All |
1 Month to 17 Years (Child) |
NCT02653404 |
IGRAManPed2014 |
TBTubercolar |
April 2015 |
April 2019 |
December 2020 |
January 12, 2016 |
May 5, 2017 |
|
- UOC Pediatria, USL9, Grosseto
Grosseto, GR, Italy - UOC Pediatria c/o Policlinico Le Scotte, Viale Mario Bracci 16
Siena, SI, Italy - UOC Malattie Infettive Universitarie c/o Policlinico Le Scotte, Viale Mario Bracci 16
Siena, Italy
|
|
| 11 |
NCT03801590 |
Not yet recruiting |
Crosslinking in Infectious Keratitis |
|
- Device: Crosslinking with Riboflavin and UV-A
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the duration for corneal ulcer healing
|
20 |
All |
Child, Adult, Older Adult |
NCT03801590 |
infectious keratitis |
|
January 1, 2019 |
January 1, 2020 |
January 1, 2021 |
January 11, 2019 |
January 11, 2019 |
|
|
|
| 12 |
NCT03715062 |
Not yet recruiting |
Reducing Antibiotic Prescriptions for Urinary Tract Infection in Long-Term Care Facilities |
|
|
Interventional
|
Not Applicable |
- Research Unit Of General Practice, Copenhagen
- Ministry of the Interior and Health, Denmark
- Velux Fonden
- Herlev Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Prescription of antibiotics for urinary tract infection
- Hospitalization
- Death
- Appropriate prescription of antibiotics for urinary tract infections
|
400 |
All |
65 Years and older (Older Adult) |
NCT03715062 |
111 |
|
December 1, 2018 |
March 31, 2019 |
March 31, 2019 |
October 22, 2018 |
October 22, 2018 |
|
|
|
| 13 |
NCT03252028 |
Recruiting |
Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients. |
- Infection, Bacterial
- Antibiotic Resistant Infection
- Diagnostic Self Evaluation
- (and 2 more...)
|
|
Observational
|
|
- Fariba Nayeri
- University Hospital, Linkoeping
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- detection of infections in intensive care unit
|
150 |
All |
Child, Adult, Older Adult |
NCT03252028 |
LINPEAS |
|
December 2, 2015 |
December 1, 2019 |
December 1, 2020 |
August 17, 2017 |
August 21, 2017 |
|
- Neurosurgery dept. University Hospital
Linkoping, Ostergotland, Sweden - Neurosurgery department, University Hospital
Linkoping, Ostergotland, Sweden
|
|
| 14 |
NCT03610581 |
Recruiting |
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With Persistent Human Papillomavirus HPV16 or HPV18 Infection of the Cervix |
- Human Papillomavirus Infections
|
- Biological: Ad26.HPV16
- Biological: Ad26.HPV18
- Biological: MVA.HPV16/18
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Janssen Vaccines & Prevention B.V.
- Bavarian Nordic
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs)
- Percentage of Participants with Unsolicited AEs
- Percentage of Participants with Serious Adverse Events (SAEs)
- Percentage of Participants with Human Papillomavirus (HPV)-Specific CD4+ and CD8+ T-Cell Responses
|
66 |
Female |
18 Years to 60 Years (Adult) |
NCT03610581 |
CR108458
2018-000200-41
VAC81623HPV1002 |
|
September 27, 2018 |
August 9, 2020 |
September 9, 2020 |
August 1, 2018 |
February 15, 2019 |
|
- Doral Medical Research
Doral, Florida, United States - Clinical Physiology Associates
Fort Myers, Florida, United States - San Marcus Research Clinic, Inc.
Miami Lakes, Florida, United States - (and 12 more...)
|
|
| 15 |
NCT03401658 |
Not yet recruiting |
Early Detection of Surgical Wound Infections Using Sensor Technology |
- Surgical Wound Infection
- Heart; Surgery, Heart, Functional Disturbance as Result
|
- Device: Sensor light detector
|
Observational
|
|
- Liverpool Heart and Chest Hospital NHS Foundation Trust
- University of Liverpool
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of surgical site infections that can reliably be detected using the sensor technology
- Proportion of patients that find the sensor technology acceptable
|
40 |
All |
Child, Adult, Older Adult |
NCT03401658 |
1175 |
SSI-Sensor |
January 2019 |
December 30, 2019 |
December 30, 2019 |
January 17, 2018 |
December 24, 2018 |
|
- Liverpool Heart and Chest Hospital
Liverpool, Merseyside, United Kingdom
|
|
| 16 |
NCT03786900 |
Available |
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727 |
- Recurrent Clostridium Difficile Infection
- Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection
|
- Biological: Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727
|
Expanded Access
|
|
- Herbert DuPont
- The University of Texas Health Science Center, Houston
|
Other |
|
|
|
|
Child, Adult, Older Adult |
NCT03786900 |
PRIM-DJ2727 |
|
|
|
|
December 25, 2018 |
December 25, 2018 |
|
|
|
| 17 |
NCT03705611 |
Recruiting |
Secondary Distribution of HIV Self-tests Through Antenatal Care Clinic Attendees and Index Clients |
|
- Diagnostic Test: HIV self-testing only
- Behavioral: HIV self-testing secondary accuracy
|
Interventional
|
Not Applicable |
- London School of Hygiene and Tropical Medicine
- World Health Organization
- Liverpool School of Tropical Medicine
- UNITAID
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Proportion of partners tested for HIV
- Number of newly diagnosed HIV positive people
- Proportion of partners of antenatal care clinic attendees who start HIV treatment, undergo circumcision, or attend discordant couples clinic
- Risk of adverse events (e.g. partnership breakdown, intimate partner violence, etc.) related to self-testing reported by antenatal care clinic attendees or HIV-positive index clients
|
10000 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03705611 |
14916 |
ANC/FRS |
September 12, 2018 |
April 30, 2019 |
April 30, 2019 |
October 15, 2018 |
October 15, 2018 |
|
- Mulanje District Hopsital
Mulanje, Malawi
|
|
| 18 |
NCT03756506 |
Recruiting |
DuraDerm® for the Reduction of Pin Track Infection |
- Infection
- Post-operative Care
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- This is a study to measure the potential reduction in pin track infection rate among research participants undergoing Deformity Correction and Traumatic Provisional Fixation. Data will be collected by clinical staff
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT03756506 |
2018-01 |
|
November 7, 2018 |
April 30, 2019 |
June 30, 2019 |
November 28, 2018 |
November 28, 2018 |
|
- Julie Morris
Saint Louis, Missouri, United States
|
|
| 19 |
NCT03656510 |
Recruiting |
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection |
- Respiratory Syncytial Virus Infections
|
- Drug: JNJ-53718678
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Respiratory Syncytial Virus (RSV) Viral Load Area Under Curve (AUC) from Immediately Prior to First Dose of Study Drug Through Day 5
- RSV Viral Load and Change from Baseline Over Time
- RSV Viral Load AUC from Immediately Prior to First Dose of Study Drug (Baseline) Through Days 3, 8, and 14
- (and 33 more...)
|
222 |
All |
up to 3 Years (Child) |
NCT03656510 |
CR108520
2016-003642-93
53718678RSV2002 |
|
November 29, 2018 |
November 27, 2020 |
November 30, 2020 |
September 3, 2018 |
January 23, 2019 |
|
- University of Arizona Health Sciences Center
Tucson, Arizona, United States - Madera Family Medical Group
Madera, California, United States - FOMAT Medical Research
Ventura, California, United States - (and 148 more...)
|
|
| 20 |
NCT03223415 |
Recruiting |
Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections |
|
- Other: Detection and isolation of C. difficile carriers
|
Interventional
|
Not Applicable |
- Yves Longtin
- Becton, Dickinson and Company
- Sir Mortimer B. Davis - Jewish General Hospital
- Jewish General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of admission screening for C. difficile carriage
- Healthcare worker compliance with the isolation precautions
- Rate of rejection of screening assays
- (and 2 more...)
|
2000 |
All |
Child, Adult, Older Adult |
NCT03223415 |
MM-CODIM-MBM-16-264
BDS-MCDIF04 |
EFFICACI |
August 25, 2017 |
February 1, 2018 |
April 30, 2018 |
July 21, 2017 |
January 17, 2018 |
|
- Hopital Charles Lemoyne
Greenfield Park, Quebec, Canada - Montreal General Hospital
Montreal, Quebec, Canada - McGill University Health Center
Montreal, Quebec, Canada - (and 2 more...)
|
|
| 21 |
NCT03563742 |
Recruiting |
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection |
- Human Immunodeficiency Virus Infections
|
- Drug: Rilpivirine 25 mg
- Drug: Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
|
Interventional
|
Phase 3 |
- Johnson & Johnson Pte Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants who are Virologic Responders (HIV-1 RNA <400 Copies/mL) at Week 24
- Percentage of Participants who are Virologic Responders (HIV-1 RNA <50 Copies/mL) at Week 24
- Percentage of Participants who are Virologic Responders (Plasma HIV-1 RNA Levels <50, <400 and <1,000 Copies/mL) at Week 48
- (and 7 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03563742 |
CR108402
TMC278HTX3001 |
RISE |
September 24, 2018 |
April 24, 2020 |
August 31, 2020 |
June 20, 2018 |
December 28, 2018 |
|
- St.Johns Medical College and Hospital
Bengaluru, India - YRGCARE
Chennai, India - Manipal University-Kasturba Medical College
Mangalore, India - (and 2 more...)
|
|
| 22 |
NCT03728413 |
Recruiting |
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus |
|
- Biological: RSV A Memphis 37
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- RSV challenge remains safe and tolerable in older adults.
- Symptom severity in RSV infection
- Viral load measurement in RSV infection
|
108 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03728413 |
11/LO/1023_V3 |
INFLAMMAGE |
November 5, 2018 |
September 28, 2023 |
September 28, 2024 |
November 2, 2018 |
November 2, 2018 |
|
- Imperial College London
London, United Kingdom
|
|
| 23 |
NCT03555981 |
Recruiting |
Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates |
- Preterm Infant
- Hypothermia, Newborn
- Death
- (and 2 more...)
|
- Other: Early Kangaroo Mother Care
- Other: Standard care
|
Interventional
|
Not Applicable |
- London School of Hygiene and Tropical Medicine
- Wellcome Trust
- Medical Research Council Unit, The Gambia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- All-cause mortality
- Time to death
- Cardio-respiratory stability
- (and 6 more...)
|
392 |
All |
up to 24 Hours (Child) |
NCT03555981 |
14545 |
eKMC |
May 20, 2018 |
June 20, 2020 |
June 20, 2020 |
June 14, 2018 |
June 14, 2018 |
|
- MRC Unit The Gambia at LSHTM
Fajara, Western Division, Gambia
|
|
| 24 |
NCT03098329 |
Recruiting |
Check it: A New Approach to Controlling Chlamydia Transmission in Young People |
- Chlamydia Trachomatis Infection
- Gonorrhea
|
|
Interventional
|
Not Applicable |
- Tulane University
- National Institutes of Health (NIH)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Rate of chlamydia in women
- Rate of gonorrhea in women
|
4854 |
Male |
15 Years to 24 Years (Child, Adult) |
NCT03098329 |
16-964337
1R01HD086794-01A1 |
|
May 22, 2017 |
April 1, 2022 |
December 31, 2022 |
March 31, 2017 |
September 12, 2018 |
|
- Tulane University School of Public Health and Tropical Medicine
New Orleans, Louisiana, United States
|
|
| 25 |
NCT03290391 |
Recruiting |
Linking Infectious and Narcology Care-Part II |
|
|
Interventional
|
Not Applicable |
- Boston Medical Center
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Undetectable HIV viral load
- Initiation of ART
- Change in CD4 count
- Retention in HIV care
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT03290391 |
H-36706
R01DA045547 |
LINC-II |
September 19, 2018 |
August 2021 |
December 2021 |
September 21, 2017 |
September 20, 2018 |
|
- First St. Petersburg Pavlov State Medical University
St. Petersburg, Russian Federation - City Addiction Hospital
St. Petersburg, Russian Federation
|
|
| 26 |
NCT03312075 |
Not yet recruiting |
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients. |
|
- Other: Sputum and blood samples
|
Observational
|
|
- University Hospital, Brest
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients screened positive for NTM by the culture
- Number of patients screened positive for NTM by serology
|
2000 |
All |
7 Years and older (Child, Adult, Older Adult) |
NCT03312075 |
CIMENT (29BRC17.0001) |
CIMENT |
January 2018 |
January 2020 |
January 2022 |
October 17, 2017 |
January 4, 2018 |
|
- CHU Amiens
Amiens, France - CHRU Brest
Brest, France - CHU Côte de Nacre
Caen, France - (and 11 more...)
|
|
| 27 |
NCT03391674 |
Not yet recruiting |
Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization |
- Antibiotic Resistant Strain
- Microbial Colonization
|
- Other: Fecal Microbiota Transplantation
|
Interventional
|
Not Applicable |
- Rambam Health Care Campus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- CRE Decolonization defined as 3 consecutive negative rectal samples for CRE
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03391674 |
0595-17-RMB |
|
March 1, 2019 |
February 28, 2020 |
October 30, 2020 |
January 5, 2018 |
August 31, 2018 |
|
|
|
| 28 |
NCT03782727 |
Not yet recruiting |
ObservAtional Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers |
|
|
Observational
|
|
- Cardiff and Vale University Health Board
- Cardiff University
- UK Dermatology Clinical Trials Network
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To ascertain the proportion of surgical site infections following excision of ulcerated skin tumours in Dermatology Departments.
|
311 |
All |
18 Years and older (Adult, Older Adult) |
NCT03782727 |
RD 17/DEC/7165 |
OASIS |
February 2019 |
October 2019 |
November 2019 |
December 20, 2018 |
December 21, 2018 |
|
- Cardiff and Vale University Health Board
Cardiff, Wales, United Kingdom
|
|
| 29 |
NCT03167398 |
Recruiting |
Fecal Microbiota Transplantation for Eradication of CRE |
- Antibiotic Resistant Strain
- Microbial Colonization
|
- Other: Fecal Microbiota Transplantation
|
Interventional
|
Not Applicable |
- Rambam Health Care Campus
- Tel-Aviv Sourasky Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- CRE eradication on rectal stool samples
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03167398 |
0215-17-RMB-CTIL |
|
February 1, 2018 |
March 30, 2019 |
October 30, 2019 |
May 30, 2017 |
September 3, 2018 |
|
- Rambam Health Care Campus
Haifa, Israel
|
|
| 30 |
NCT03630250 |
Recruiting |
Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA) |
- Meningitis, Bacterial
- Neisseria Infection
|
|
Interventional
|
Early Phase 1 |
- University of Southampton
- University Hospital Southampton NHS Foundation Trust
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring respiratory rate.
- Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring body temperature.
- Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring heart rate.
- (and 2 more...)
|
88 |
All |
18 Years to 45 Years (Adult) |
NCT03630250 |
NadA-Lac4 |
NadA-Lac4 |
October 18, 2018 |
September 1, 2019 |
September 1, 2020 |
August 14, 2018 |
November 7, 2018 |
|
- NIHR Southampton Clinical Research Facility
Southampton, United Kingdom
|
|
| 31 |
NCT00945152 |
Recruiting |
Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM) |
- Bacterial Infections
- Wounds
|
- Drug: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)
- Drug: Placebo, complex gel formulation without Vancomycin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eliminate MRSA infection
- More rapid healing of cSSTI
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT00945152 |
WIRB study # 1111446
None yet, self funding |
Vancogel(R) |
July 2011 |
December 2019 |
December 2019 |
July 23, 2009 |
August 7, 2018 |
|
- Robert S Berman MD / 2141 Alt. A1A South, Suite 450
Jupiter, Florida, United States
|
|
| 32 |
NCT03395743 |
Available |
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic |
|
|
Expanded Access
|
|
- AmpliPhi Biosciences Corporation
|
Industry |
|
|
|
|
Child, Adult, Older Adult |
NCT03395743 |
AB-PA01-EAP01 |
|
|
|
|
January 10, 2018 |
January 10, 2018 |
|
|
|
| 33 |
NCT03691610 |
Recruiting |
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
- Healthy Volunteers (Meningococcal Infection)
|
- Biological: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine
- Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
- Biological: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine
- (and 8 more...)
|
Interventional
|
Phase 3 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Antibody titers against meningococcal serogroups A, C, Y, and W
- Antibody titers ≥ 1:8 against meningococcal serogroups A, C, Y, and W
- Number of participants reporting solicited injection site reactions or systemic reactions
|
940 |
All |
6 Months to 19 Months (Child) |
NCT03691610 |
MET61
U1111-1205-2836 |
|
October 4, 2018 |
July 2020 |
July 2020 |
October 2, 2018 |
February 5, 2019 |
|
- Investigational Site Number 8400036
Birmingham, Alabama, United States - Investigational Site Number 8400009
Dothan, Alabama, United States - Investigational Site Number 8400013
Phoenix, Arizona, United States - (and 24 more...)
|
|
| 34 |
NCT03673462 |
Recruiting |
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
- Healthy Volunteers (Meningococcal Infection)
|
- Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine)
- Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)
- Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Solicited injection site reactions and systemic reactions
|
3080 |
All |
42 Days to 89 Days (Child) |
NCT03673462 |
MET41
U1111-1183-6261 |
MET41 |
September 17, 2018 |
April 2021 |
April 2021 |
September 17, 2018 |
September 25, 2018 |
|
- Investigational Site Number 8400049
Birmingham, Alabama, United States - Investigational Site Number 8400059
Jonesboro, Arkansas, United States - Investigational Site Number 8400039
Downey, California, United States - (and 22 more...)
|
|
| 35 |
NCT03387397 |
Recruiting |
Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities |
|
|
Interventional
|
Not Applicable |
- Northwell Health
- Gilead Sciences
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Self-reported adherence to antiretroviral therapy (ART)
- Quality of Life (QoL)
- Patients' illness-specific symptoms and medication-specific side effects
- (and 10 more...)
|
170 |
All |
18 Years and older (Adult, Older Adult) |
NCT03387397 |
17-0063 |
TEAMH |
December 12, 2017 |
December 2018 |
July 2019 |
January 2, 2018 |
August 28, 2018 |
|
- Center for AIDS Research and Treatment
Manhasset, New York, United States
|
|
| 36 |
NCT03113123 |
Recruiting |
Prevention of HIV in "Île-de-France" |
|
|
Interventional
|
Not Applicable |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction of new HIV diagnosis
- Number of recent infections
- Prevalence of HIV-infection at the screening visit (undiagnosed epidemic)
- (and 14 more...)
|
3000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03113123 |
ANRS PREVENIR
2016-A01577-44 |
ANRS-PREVENIR |
May 3, 2017 |
April 2020 |
October 2020 |
April 13, 2017 |
May 15, 2017 |
|
- Hôpital Avicenne
Bobigny, France - Hôpital Jean Verdier
Bondy, France - Hôpital Ambroise-Paré
Boulogne, France - (and 19 more...)
|
|
| 37 |
NCT03598842 |
Not yet recruiting |
Tuberculosis - Learning the Impact of Nutrition |
- Tuberculosis
- Malnutrition
- Helminth Infection
|
- Dietary Supplement: Nutritional Supplementation Meals
- Dietary Supplement: Multivitamin
- Drug: Anti-parasitic medications
|
Interventional
|
Not Applicable |
- Boston Medical Center
- Rutgers, The State University of New Jersey
- Jawaharlal Institute of Postgraduate Medical Education & Research
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Immune response
- Immune Response
- Anthropometric measurement
- Anthropometric measurements
|
120 |
All |
18 Years to 55 Years (Adult) |
NCT03598842 |
H-37473
6005415 |
TB-LION |
March 2019 |
December 2023 |
December 2023 |
July 25, 2018 |
February 12, 2019 |
|
|
|
| 38 |
NCT03060629 |
Recruiting |
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
|
- Biological: Ad26.Mos4.HIV
- Biological: Clade C gp140
- Biological: Placebo
|
Interventional
|
Phase 2 |
- Janssen Vaccines & Prevention B.V.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Vaccine Efficacy (VE) as Derived From Confirmed HIV-1 Infections Diagnosed Between the Month 7 and Month 24 Visits
- Percentage of Participants Experiencing Reactogenicity Sign or Symptom
- Percentage of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- (and 9 more...)
|
2600 |
Female |
18 Years to 35 Years (Adult) |
NCT03060629 |
CR108263
VAC89220HPX2008
HVTN 705
HVTN 705/VAC89220HPX2008 |
|
November 3, 2017 |
November 2, 2020 |
February 1, 2022 |
February 23, 2017 |
November 7, 2018 |
|
- UNC Lilongwe Project
Lilongwe, Malawi - Polana Caniço Health Research and Training Center (CISPOC)
Maputo, Mozambique - Josha Research
Bloemfontein, South Africa - (and 22 more...)
|
|
| 39 |
NCT03379675 |
Recruiting |
A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus |
- Respiratory Syncytial Virus Infections
|
- Drug: JNJ-53718678 500 mg
- Drug: JNJ-53718678 80 mg
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Area Under the Viral Load-time Curve (AUC)
- RSV (Respiratory Syncytial Virus) Viral Load Over Time
- Change from Baseline in RSV Viral Load Over Time
- (and 12 more...)
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03379675 |
CR108419
2017-003252-24
53718678RSV2004 |
|
February 6, 2018 |
July 18, 2019 |
August 8, 2019 |
December 20, 2017 |
January 23, 2019 |
|
- Core Healthcare Group
Cerritos, California, United States - eStudySite
Chula Vista, California, United States - SC Clinical Research Inc
Garden Grove, California, United States - (and 118 more...)
|
|
| 40 |
NCT02897180 |
Recruiting |
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia |
- Close Contacts of Active Tuberculosis
|
- Biological: Nyaditum resae(R)
- Biological: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Fundació Institut Germans Trias i Pujol
- National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Efficacy, incidence of confirmed cases of active TB
- Efficacy, incidence of all cases of active TB and mortality (all causes)
- Incidence of adverse events during the administration of the NR
|
3300 |
All |
5 Years and older (Child, Adult, Older Adult) |
NCT02897180 |
NYADAGEORG |
|
March 10, 2017 |
October 2020 |
March 2021 |
September 13, 2016 |
September 7, 2017 |
|
- National Center for Tuberculosis and Lung Diseases
Tbilisi, Georgia
|
|
| 41 |
NCT03303625 |
Recruiting |
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age |
- Respiratory Syncytial Viruses
- Respiratory Tract Infections
|
- Biological: Ad26.RSV.preF (1*10^11 vp)
- Biological: Ad26.RSV.preF (5*10^10 vp)
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Janssen Vaccines & Prevention B.V.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Percentage of Participants With Solicited Local Adverse Events (AEs)
- Percentage of Participants With Solicited Systemic AEs
- Percentage of Participants With Unsolicited AEs
- (and 4 more...)
|
60 |
All |
12 Months to 50 Years (Child, Adult) |
NCT03303625 |
CR108371
2017-001345-27
VAC18194RSV2001 |
|
November 29, 2017 |
June 26, 2020 |
June 26, 2020 |
October 6, 2017 |
January 23, 2019 |
|
- Heartland Research Associates, LLC
Newton, Kansas, United States - The Children's Mercy Hospital
Kansas City, Missouri, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States - (and 6 more...)
|
|
| 42 |
NCT00404989 |
Recruiting |
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. |
- HIV Infections
- Hepatitis B
|
|
Observational
|
|
- Syneos Health
- AbbVie
- Apotex Inc.
- (and 27 more...)
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1600 |
Female |
12 Years to 60 Years (Child, Adult) |
NCT00404989 |
APR |
APR |
January 1989 |
January 2099 |
January 2099 |
November 29, 2006 |
July 10, 2018 |
|
- Registry Coordinating Center
Wilmington, North Carolina, United States
|
|
| 43 |
NCT03397433 |
Recruiting |
ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record |
|
- Other: Information Technology physician assist
|
Interventional
|
Not Applicable |
- NorthShore University HealthSystem Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in length of stay
- Rapid response to initial therapy
- Reduced cost of ancillary testing
- (and 7 more...)
|
6000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03397433 |
EH13-368 |
ANSWER |
June 2015 |
July 2018 |
October 2018 |
January 12, 2018 |
January 12, 2018 |
|
- NorthShore University HealthSystem Research Institute
Evanston, Illinois, United States
|
|
| 44 |
NCT03832023 |
Not yet recruiting
New |
Community-based Tuberculosis Tracing and Preventive Therapy |
|
- Other: Screening and initiating preventive therapy in communities
|
Interventional
|
Not Applicable |
- Elizabeth Glaser Pediatric AIDS Foundation
- Epicentre
- University of Sheffield
- Institut de Recherche pour le Developpement
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Completion of preventive therapy
- Proportion of children screened
- Proportion of children eligible for PT
- (and 27 more...)
|
1500 |
All |
Child, Adult, Older Adult |
NCT03832023 |
EG0211 |
CONTACT |
July 1, 2019 |
April 14, 2021 |
April 14, 2021 |
February 6, 2019 |
February 6, 2019 |
|
- Hôpital de district Bonassama
Bonabéri, Cameroon - Hôpital de district Log-Baba
Douala, Cameroon - Centre Médical d'arrondissement Delangue
Edéa, Cameroon - (and 22 more...)
|
|
| 45 |
NCT03834376 |
Available
New |
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection |
- H7N9 Subtype of Influenza A Virus
|
|
Expanded Access
|
|
- Janssen Research & Development, LLC
|
Industry |
|
|
|
All |
13 Years and older (Child, Adult, Older Adult) |
NCT03834376 |
CR108461
63623872FLZ4001 |
|
|
|
|
February 8, 2019 |
February 8, 2019 |
|
|
|
| 46 |
NCT03292432 |
Recruiting |
Triggered Escalating Real-time Adherence (TERA) Intervention |
|
- Behavioral: TERA Intervention
- Behavioral: Standard of Care
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Mental Health (NIMH)
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Proportion of participants with plasma Human Immunodeficiency Virus - Type I ribonucleic acid (HIV-1 RNA) levels less than (<) 50 copies/mL at week 12
- Proportion of participants with HIV-1 RNA < 200 copies/mL at week 12
- Proportion of participants with HIV-1 RNA < 50 copies/mL at weeks 24, 36 and 48
- (and 5 more...)
|
120 |
All |
13 Years to 24 Years (Child, Adult) |
NCT03292432 |
17-1458
5U24HD089880-02 |
TERA |
February 1, 2018 |
January 2020 |
March 2020 |
September 25, 2017 |
January 18, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - David Geffen School of Medicine at UCLA
Los Angeles, California, United States - University of Colorado Denver Children's Hospital Colorado
Aurora, Colorado, United States - (and 7 more...)
|
|
| 47 |
NCT03776786 |
Recruiting |
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans |
- Treatment of Acute Yellow Fever Virus Infection
|
- Biological: TY014
- Other: 0.9% Saline
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)
- Percentage Aviremia Post Treatment (Efficacy Arm only)
- Maximum Concentration (Cmax) - Pharmacokinetic Assessment
- (and 7 more...)
|
67 |
All |
21 Years to 50 Years (Adult) |
NCT03776786 |
YFT-001
CTA1800118 |
|
December 6, 2018 |
June 30, 2019 |
September 30, 2019 |
December 17, 2018 |
December 19, 2018 |
|
- SingHealth Investigational Medicine Unit
Singapore, Singapore
|
|
| 48 |
NCT03740646 |
Not yet recruiting |
Pneumocystis Primary Infection in Non-immunosuppressed Infants |
|
|
Observational
|
|
- University Hospital, Brest
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Pneumocystis presence or not in nasopharyngeal specimens from newborns and infants
|
400 |
All |
up to 12 Months (Child) |
NCT03740646 |
CAPRI-PC( 29BRC18.0052) |
CAPRI-PC |
November 2018 |
December 2020 |
December 2020 |
November 14, 2018 |
November 14, 2018 |
|
- CHRU de Brest
Brest, France
|
|
| 49 |
NCT03660839 |
Recruiting |
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria |
- Plasmodium Falciparum Infection
|
- Drug: Artefenomel OZ439
- Drug: Ferroquine SSR97193
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PCR-corrected ACPR
- PCR-crude ACPR
- Parasitemia
- (and 19 more...)
|
140 |
All |
14 Years to 69 Years (Child, Adult, Older Adult) |
NCT03660839 |
ACT14655
U1111-1191-5573 |
|
September 5, 2018 |
October 2019 |
October 2019 |
September 7, 2018 |
December 20, 2018 |
|
- Investigational Site Number 2040001
Cotonou, Benin - Investigational Site Number 8540002
Ouagadougou, Burkina Faso - Investigational Site Number 8540001
Ouagadougou, Burkina Faso - (and 2 more...)
|
|
| 50 |
NCT02497612 |
Recruiting |
To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria |
- Plasmodium Falciparum Infection
|
- Drug: Ferroquine SSR97193
- Drug: Artefenomel
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of patients with Polymerase Reaction Chain (PCR)-adjusted Adequate Clinical and Parasitological Response (ACPR)
- Percentage of patients with PCR - adjusted ACPR
- Percentage of patients with PCR - crude ACPR
- (and 7 more...)
|
662 |
All |
6 Months to 69 Years (Child, Adult, Older Adult) |
NCT02497612 |
DRI12805
U1111-1155-7960 |
FALCI |
July 25, 2015 |
April 2, 2021 |
April 2, 2021 |
July 14, 2015 |
October 9, 2018 |
|
- Investigational Site Number 204001
Cotonou, Benin - Investigational Site Number 854001
Nanoro, Burkina Faso - Investigational Site Number 854003
Niangoloko, Burkina Faso - (and 11 more...)
|
|
| 51 |
NCT03376321 |
Recruiting |
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection |
|
- Drug: Pimodivir 600 mg
- Drug: Placebo
- Other: SOC Treatment
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Participant's Clinical Status Assessed by Hospital Recovery Scale
- Number of Participants With Adverse Events as a Measure of Safety and Tolerability
- Number of Participants With Laboratory Abnormalities as a Measure of Safety and Tolerability
- (and 25 more...)
|
600 |
All |
13 Years to 85 Years (Child, Adult, Older Adult) |
NCT03376321 |
CR108399
2017-002156-84
63623872FLZ3001 |
|
January 3, 2018 |
April 2, 2020 |
May 1, 2020 |
December 18, 2017 |
January 23, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Nea Baptist Clinic
Jonesboro, Arkansas, United States - UCSF Fresno
Fresno, California, United States - (and 356 more...)
|
|
| 52 |
NCT03381196 |
Recruiting |
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications |
|
- Drug: Pimodivir 600 mg
- Drug: Placebo
- Other: SOC Treatment
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Resolution of Influenza-Related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ)
- Number of Participants With Adverse Events as a Measure of Safety and Tolerability
- Number of Participants With Laboratory Abnormalities as a Measure of Safety and Tolerability
- (and 17 more...)
|
720 |
All |
13 Years to 85 Years (Child, Adult, Older Adult) |
NCT03381196 |
CR108400
2017-002217-59
63623872FLZ3002 |
|
January 18, 2018 |
May 19, 2019 |
October 29, 2019 |
December 21, 2017 |
January 30, 2019 |
|
- Cahaba Research Inc
Birmingham, Alabama, United States - Scottsboro Quick Care Clinic
Scottsboro, Alabama, United States - Research Center of Fresno Inc
Fresno, California, United States - (and 415 more...)
|
|
| 53 |
NCT03225794 |
Recruiting |
Simian Foamy Virus Transmission to Humans |
- Simian Foamy Virus Infection (Disorder)
|
- Diagnostic Test: Simian foamy virus Infection
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Infection with simian foamy virus by determination of the presence of specific antibodies in plasma
- Infection with simian foamy virus by determination of the presence viral DNA in blood cells
|
1600 |
All |
5 Years to 90 Years (Child, Adult, Older Adult) |
NCT03225794 |
2010-27 |
|
November 1, 2010 |
October 2020 |
October 2020 |
July 21, 2017 |
August 8, 2018 |
|
- Centre Pasteur du CAmeroun
Yaoundé, Cameroon
|
|
| 54 |
NCT03361956 |
Recruiting |
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection |
|
- Drug: JNJ-56136379
- Drug: Placebo
- Drug: NA (ETV or TDF)
|
Interventional
|
Phase 2 |
- Janssen Sciences Ireland UC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Main Study: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels at Week 24
- Main Study: Number of Participants With Adverse Events (AEs)
- Main Study: Number of Participants With Serious Adverse Events (SAEs)
- (and 15 more...)
|
220 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03361956 |
CR108410
2017-001110-29
56136379HPB2001 |
|
February 13, 2018 |
October 18, 2019 |
March 31, 2021 |
December 5, 2017 |
January 23, 2019 |
|
- The Office of Franco Felizarta, MD
Bakersfield, California, United States - Scripps Clinic
La Jolla, California, United States - Orlando Immunology Center
Orlando, Florida, United States - (and 81 more...)
|
|
| 55 |
NCT01492036 |
Recruiting |
Long-Term Follow-Up of Recipient of Gene Transfer Research |
- Retroviridae Infections
- Cancer
|
- Other: Blood Tests
- Behavioral: Questionnaires
|
Observational
|
|
- M.D. Anderson Cancer Center
- National Center for Research Resources (NCRR)
- National Cancer Institute (NCI)
- Ziopharm
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Document Long-Term Safety of Gene-Transfer Research
|
130 |
All |
Child, Adult, Older Adult |
NCT01492036 |
2006-0676
R01CA124782
R01CA141303 |
|
December 2011 |
December 2026 |
December 2026 |
December 14, 2011 |
July 6, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 56 |
NCT03803683 |
Not yet recruiting |
Improving Health Outcomes in Young Men (mLab App) |
|
- Device: mLab App
- Behavioral: HIV Prevention Information
|
Interventional
|
Not Applicable |
- Rebecca Schnall, RN, MPH, PhD
- Columbia University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Total number of youth tested for HIV
- Total number of HIV negative/ positive results
- Total number of youth who link to HIV care services
- (and 2 more...)
|
500 |
Male |
18 Years to 29 Years (Adult) |
NCT03803683 |
AAAR8760 |
|
February 2019 |
October 2022 |
May 2023 |
January 14, 2019 |
January 14, 2019 |
|
- Lurie Children's Hospital
Chicago, Illinois, United States - Columbia University School of Nursing
New York, New York, United States
|
|
| 57 |
NCT02931539 |
Recruiting |
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir |
|
- Drug: Maribavir
- Drug: Ganciclovir
- Drug: Valganciclovir
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of Participants who Achieve Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8
- Proportion of Participants who Achieve CMV Viremia Clearance and Tissue-invasive CMV Disease or CMV Syndrome Improvement or Resolution
- Proportion of Participants who Achieve Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) After 8 Weeks of Receiving Study-assigned Treatment
- (and 21 more...)
|
351 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02931539 |
SHP620-303
2015-004725-13 |
|
December 29, 2016 |
May 6, 2019 |
May 6, 2019 |
October 13, 2016 |
January 16, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Banner University of Arizona Medical Center
Tucson, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - (and 132 more...)
|
|
| 58 |
NCT03057119 |
Recruiting |
Feasibility of SBIRT-PN |
- Substance Use
- HIV/AIDS
- Older Adults
- (and 2 more...)
|
- Behavioral: Psycho-educational content (5 Minutes)
- Behavioral: Readiness Assessment (10 minutes)
- Behavioral: Goal-Setting (5 minutes)
- (and 2 more...)
|
Interventional
|
Not Applicable |
- University of Florida
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Feasibility Calculation & Acceptability Questionaire
- Substance Use Treatment Engagement
- Substance use NIDA STTR Drug and Alcohol Use Measure
- Biologically Confirmed Drug Use
|
100 |
All |
50 Years to 100 Years (Adult, Older Adult) |
NCT03057119 |
IRB201701252 - N
1K23DA039769-01
KL2TR001429 |
|
January 29, 2018 |
December 30, 2020 |
March 30, 2021 |
February 17, 2017 |
August 15, 2018 |
|
- University of Florida
Gainesville, Florida, United States - Department of Health in Columbia County",
Lake City, Florida, United States
|
|
| 59 |
NCT02927067 |
Recruiting |
Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients |
|
- Drug: Maribavir
- Drug: Valganciclovir
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- EFFICACY OF MARIBAVIR COMPARED TO VALGANCICLOVIR IN CONFMIRMED CMV VIREMIA CLEARANCE AT THE END OF STUDY WEEK 8, REGARDLESS OF WHETHER STUDY ASSIGNED TREATMENT WAS COMPLETED
- MAINTENANCE OF CONFIRMED CMV VIREMIA CLEARANCE ACHIEVED AT THE END OF STUDY WEEK 8 THROUGH STUDY WEEK 16.
- ACHIEVEMENT CONFIRMED CMV VIREMIA CLEARANCE AFTER 8 WEEKS OF RECEIVING STUDY-ASSIGNED TREATMENT
- (and 6 more...)
|
550 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT02927067 |
SHP620-302
2015-004726-34 |
|
April 6, 2017 |
August 13, 2021 |
August 13, 2021 |
October 6, 2016 |
July 17, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - UCLA Medical Center
Los Angeles, California, United States - Stanford University
Stanford, California, United States - (and 86 more...)
|
|
| 60 |
NCT03394196 |
Recruiting |
RESIST-2: 2nd-line ART for HIV-2 Infection |
|
- Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS
- Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
- Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)
|
Interventional
|
Not Applicable |
- University of Washington
- Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal
- Centre de Sante de Ziguinchor, Casamance, Senegal
- (and 3 more...)
|
Other / Industry / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death
- Loss to follow up
- Virologic Failure on 2nd line ART
- (and 4 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03394196 |
STUDY00000228
R01AI120765 |
RESIST-2 |
July 4, 2018 |
January 2021 |
July 2021 |
January 9, 2018 |
July 26, 2018 |
|
- Centre de Sante de Ziguinchor
Ziguinchor, Casamance, Senegal - Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann
Dakar, Senegal
|
|
| 61 |
NCT03133728 |
Not yet recruiting |
Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants |
|
- Diagnostic Test: Alere Q Testing
|
Observational
|
|
- University of Alabama at Birmingham
- Centre for Infectious Disease Research in Zambia
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Observational Model: Other
- Time Perspective: Other
|
- Uptake of Antiretroviral Therapy (ART) among HIV-infected Infants and Young Children (IYC)
- Age at first early infant HIV testing among HIV-exposed IYCs
- 3-month survival for HIV-infected IYC receiving ART
- (and 8 more...)
|
1628 |
All |
up to 17 Months (Child) |
NCT03133728 |
UAB Neo 016 |
CDC Detect |
April 1, 2019 |
January 1, 2020 |
January 1, 2021 |
April 28, 2017 |
January 28, 2019 |
|
|
|
| 62 |
NCT03230058 |
Recruiting |
Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis |
|
- Drug: Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
|
Interventional
|
Phase 2
Phase 3 |
- L.V. Prasad Eye Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Success or failure
- Best-corrected visual acuity
|
55 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT03230058 |
GMRV_NATA01 |
NATA_VORI |
January 1, 2017 |
March 1, 2018 |
September 30, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- GMRV Campus LV Prasad Eye Insitute
Visakhapatnam, Andhra Pradesh, India
|
|
| 63 |
NCT02194712 |
Recruiting |
Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact |
|
- Other: Urine CAA detection
|
Observational
|
|
- Meta Roestenberg
- Leiden University Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The sensitivity and specificity of UCP-CAA
- The percentage of travellers with persisting positive UCP-CAA six weeks after conventional praziquantel treatment
|
155 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02194712 |
CAA48780 |
|
January 2015 |
June 2019 |
June 2019 |
July 18, 2014 |
July 24, 2018 |
|
- Academic Medical Center
Amsterdam, Netherlands - Leiden University Medical Center
Leiden, Netherlands - Harbour Hospital
Rotterdam, Netherlands
|
|
| 64 |
NCT03487848 |
Recruiting |
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection |
- Hepatitis C
- Chronic Hepatitis
|
- Drug: Daclatasvir
- Drug: Sofosbuvir
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum observed concentration (Cmax) derived from plasma concentration for Daclatasvir
- Time taken to reach maximum concentration (Tmax) derived from plasma concentration for Daclatasvir
- Area under the concentration-time curve in one dosing interval [AUC(TAU)] derived from plasma concentration for Daclatasvir
- (and 10 more...)
|
30 |
All |
3 Years to 17 Years (Child) |
NCT03487848 |
AI444-423 |
|
May 18, 2018 |
April 29, 2021 |
February 28, 2023 |
April 4, 2018 |
November 27, 2018 |
|
- Local Institution
Melbourne, Victoria, Australia - Local Institution
Wuppertal, Germany - Local Institution
Krakow, Poland - (and 4 more...)
|
|
| 65 |
NCT02727933 |
Recruiting |
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Frequency of expected and unexpected adverse reactions (AEs) and serious adverse events (SAEs)/reactions. These include laboratory abnormalities
- Incidence proportion of AEs leading to discontinuation of study therapy
- Incidence rate of AEs leading to discontinuation of study therapy
- (and 3 more...)
|
1770 |
All |
19 Years and older (Adult, Older Adult) |
NCT02727933 |
AI444-335 |
|
November 3, 2017 |
September 30, 2020 |
September 30, 2020 |
April 5, 2016 |
June 11, 2018 |
|
- Local Institution
Seoul, Korea, Republic of
|
|
| 66 |
NCT02662829 |
Recruiting |
Preventing Childhood Tuberculosis in Lesotho (PREVENT Study) |
|
- Behavioral: Community-based intervention
- Other: Standard of care
|
Interventional
|
Not Applicable |
- Columbia University
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Yield of child contacts
- Percentage of IPT initiation
- Percentage of IPT completion
- Percentage of HIV testing
|
1160 |
All |
Child, Adult, Older Adult |
NCT02662829 |
AAAN7358
K01AI104351 |
|
December 2015 |
December 2018 |
May 2019 |
January 26, 2016 |
July 21, 2017 |
|
- Berea Hospital
Berea, Berea District, Lesotho - Holy Family Health Center
Berea, Berea District, Lesotho - Khubetsoana Health Center
Berea, Berea District, Lesotho - (and 7 more...)
|
|
| 67 |
NCT03340077 |
Not yet recruiting |
The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients |
|
- Other: Medicines Optimisation Review toolkit
- Other: Standard of Care
|
Interventional
|
Not Applicable |
- Brighton and Sussex University Hospitals NHS Trust
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Differences in the number of medication related problems
- The number of unresolved medication related problems
- Drug and Drug interactions:
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03340077 |
MOR study |
MOR |
January 6, 2018 |
July 6, 2020 |
July 6, 2020 |
November 13, 2017 |
November 13, 2017 |
|
|
|
| 68 |
NCT02641106 |
Recruiting |
VDOT for Monitoring Adherence to LTBI Treatment |
- Tuberculosis
- Latent Tuberculosis Infection
|
- Other: Video Directly Observed Therapy
- Other: In-Person DOT
|
Interventional
|
Not Applicable |
- University of California, San Diego
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of participants completing LTBI treatment
- Participant satisfaction with method of monitoring LTBI treatment
- cost-effectiveness of VDOT compared to in-person DOT for administering 3HP
- (and 2 more...)
|
310 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT02641106 |
150155 |
VMALT |
March 8, 2016 |
December 2019 |
December 2019 |
December 29, 2015 |
October 11, 2018 |
|
- San Diego County Health and Human Services Agency
San Diego, California, United States
|
|
| 69 |
NCT03526718 |
Recruiting |
Improved Understanding of Ongoing Transmission of Leprosy in the Hyperendemic Comoros (ComLep) |
|
|
Observational
|
|
- Institute of Tropical Medicine, Belgium
- Damien Foundation
- Programme National de lutte contre la Lèpre et la Tuberculose, Comores
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Leprosy incidence among contacts of an index patient
- Recent transmission cluster
- Patient and health system delay.
|
450 |
All |
Child, Adult, Older Adult |
NCT03526718 |
1147/16 |
ComLep |
April 1, 2017 |
December 2019 |
December 2020 |
May 16, 2018 |
May 16, 2018 |
|
- Damien Foundation
Moutsamoudou, Anjouan, Comoros
|
|
| 70 |
NCT03629080 |
Recruiting |
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients |
- Cytomegalovirus (CMV) Infection
- Kidney Transplantation
|
- Biological: HB-101 vaccine
- Biological: placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Incidence of adverse events from the time of first injection of study drug (3 months prior to transplant) up to 12 months post-transplant follow-up.
- Incidence of adverse events of special interest from post-transplant (graft rejection, CMV syndrome and disease assessment) to the End of Study Visit.
- Measure Oral Body Temperature.
- (and 15 more...)
|
150 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03629080 |
H-100-002
2017-005047-32 |
|
December 12, 2018 |
January 15, 2021 |
January 15, 2021 |
August 14, 2018 |
February 1, 2019 |
|
- California Institute of Renal Research
La Mesa, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 4 more...)
|
|
| 71 |
NCT02808507 |
Recruiting |
Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa |
|
- Other: Active TB case finding
|
Interventional
|
Not Applicable |
- Johns Hopkins Bloomberg School of Public Health
- National Institute of Allergy and Infectious Diseases (NIAID)
- Perinatal HIV Research Unit of the University of the Witswatersrand
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of TB cases started on TB treatment per cluster (clinic)
- Acceptability of active TB case-finding strategies
- Reach of active TB case-finding strategies
- (and 3 more...)
|
128171 |
All |
up to 99 Years (Child, Adult, Older Adult) |
NCT02808507 |
15-0005
R01AI116787-02 |
Kharitode TB |
July 18, 2016 |
January 17, 2018 |
January 17, 2020 |
June 21, 2016 |
August 10, 2018 |
|
- Vhembe health subdistrict
Louis Trichardt, Limpopo, South Africa - Waterberg health subdistrict
Mokopane, Limpopo, South Africa
|
|
| 72 |
NCT02703389 |
Recruiting |
Improving Knowledge Translation Upon Emergency Department Discharge |
|
- Behavioral: Video
- Behavioral: Pamphlet
|
Interventional
|
Phase 3 |
- Hamilton Health Sciences Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of participants who fill antimicrobial prescription early
- Proportion of participants who fill antimicrobial prescription inappropriately early
- Caregiver satisfaction with management plan (treatment arm)
- Caregiver retention of stewardship knowledge
|
100 |
All |
6 Months to 5 Years (Child) |
NCT02703389 |
NIF-2015-1123 |
|
January 2017 |
December 2018 |
April 2019 |
March 9, 2016 |
August 2, 2018 |
|
- McMaster Children's Hospital
Hamilton, Ontario, Canada
|
|
| 73 |
NCT03360422 |
Recruiting |
ANCHORS Study: UH2 Project |
|
- Other: Survey
- Other: Focus Group
- Other: Usability study
|
Interventional
|
Not Applicable |
- University of Florida
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Quantity of alcohol consumption
- High-risk sexual behavior
- Study participant opinions on intervention content
|
751 |
Male |
18 Years to 30 Years (Adult) |
NCT03360422 |
IRB201701367 N
UH2AA026214-01 |
ANCHORS |
December 1, 2017 |
July 2019 |
August 2019 |
December 4, 2017 |
July 4, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
|
| 74 |
NCT03395769 |
Available |
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic |
|
|
Expanded Access
|
|
- AmpliPhi Biosciences Corporation
|
Industry |
|
|
|
|
Child, Adult, Older Adult |
NCT03395769 |
AB-SA01-EAP01 |
|
|
|
|
January 10, 2018 |
January 10, 2018 |
|
|
|
| 75 |
NCT03463694 |
Not yet recruiting |
Edinburgh and Lothian Virus Intervention Study in Kids |
- Upper Respiratory Tract Infections
- Virus
- Virus Shedding
- Pediatric ALL
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to the first report that the child is "not unwell".
- Severity of all symptoms
- The length of time for individual symptoms to resolve
- (and 19 more...)
|
480 |
All |
40 Weeks to 7 Years (Child) |
NCT03463694 |
ELVIS Kids |
ELVIS Kids |
November 2018 |
May 2020 |
January 2021 |
March 13, 2018 |
October 25, 2018 |
|
|
|
| 76 |
NCT03528135 |
Recruiting |
Project PRIDE (Promoting Resilience In Discriminatory Environments) |
- Human Immunodeficiency Virus
- Sexually Transmitted Infections
- Anxiety
- (and 2 more...)
|
- Behavioral: Project PRIDE
|
Interventional
|
Not Applicable |
- University of Houston
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in 60-Day Condomless Anal Sex in the Absence of PrEP from pre-test to 5 months
- Salivary cortisol
- 60-Day Drug Use
- (and 16 more...)
|
123 |
All |
18 Years to 25 Years (Adult) |
NCT03528135 |
111889
1R21DA041250-01A1 |
|
November 9, 2018 |
April 30, 2019 |
April 30, 2019 |
May 17, 2018 |
December 4, 2018 |
|
- Avenue 360, University of Houston
Houston, Texas, United States
|
|
| 77 |
NCT03168945 |
Recruiting |
Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa |
|
- Other: GeneXpert MTB/RIF
- Other: Smear microscopy
|
Interventional
|
Not Applicable |
- University of Cape Town
- Medical Research Council, South Africa
- National Institutes of Health (NIH)
- University of Cape Town Lung Institute
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- The time-to-treatment of culture-positive TB cases initiating TB treatment in each study arm.
- The proportion of culture-positive TB cases initiating TB treatment in each study arm.
- The proportion of culture-positive TB cases completing 6-months of TB treatment in each study arm.
- (and 7 more...)
|
600 |
All |
18 Years and older (Adult, Older Adult) |
NCT03168945 |
XACT-2
OISE-16-62105-1 |
XACT-2 |
November 2016 |
November 2020 |
November 2020 |
May 30, 2017 |
May 30, 2017 |
|
- University of Cape Town
Cape Town, Western Province, South Africa
|
|
| 78 |
NCT02774382 |
Recruiting |
Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections |
|
- Drug: Vancomycin
- Drug: Fecal microbiota transplantation
- Drug: Rectal bacteriotherapy
|
Interventional
|
Phase 3 |
- Hvidovre University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical cure of recurrent Clostridium difficile infection defined as patient-reported abscence of Clostridium difficile infection 90 days after treatment.
- Early or late recurrence of CDI after the end of treatment defined as recurrence of symptoms of CDI and a positive stool sample with Clostridium difficile (PCR).
- Days with diarrhea
- (and 13 more...)
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT02774382 |
SJ-478 |
|
May 1, 2017 |
December 2018 |
January 2019 |
May 17, 2016 |
September 27, 2017 |
|
- Hvidovre Hospital
Hvidovre, Denmark - Køge sygehus
Køge, Denmark
|
|
| 79 |
NCT01439503 |
Recruiting |
Safer Sex Program for Young African-American Men |
- Gonorrhea
- Chlamydia
- Trichomoniasis
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- Richard Crosby
- National Institute of Mental Health (NIMH)
- University of Kentucky
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- The frequency of unprotected sex rather than frequency of condom use will be used as the primary outcome measure.
|
620 |
Male |
15 Years to 29 Years (Child, Adult) |
NCT01439503 |
11-0204-F3R
1R01MH092226-01A1 |
|
September 2012 |
May 2018 |
May 2019 |
September 23, 2011 |
October 30, 2017 |
|
- Mississippi State Department of Health STD Clinic
Jackson, Mississippi, United States
|
|
| 80 |
NCT00557726 |
Recruiting |
Diagnosis and Management of Inflammatory and Infectious Diseases |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
|
250 |
All |
3 Years and older (Child, Adult, Older Adult) |
NCT00557726 |
780023
78-I-0023 |
|
February 17, 1978 |
|
|
November 14, 2007 |
January 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 81 |
NCT03348254 |
Recruiting |
Antibiotic Prophylaxis in Primary Joint Arthroplasty of the Hip and Knee. |
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Antibiotic Prophylaxis
|
- Drug: Single shot antibiotic prophylaxis
- Drug: Multiple shot antibiotic prophylaxis
|
Observational
|
|
- Onze Lieve Vrouwe Gasthuis
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Revision arthroplasty because of infection
|
150000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03348254 |
OLVG AB Profylaxe Veltman |
|
April 2016 |
June 2020 |
August 2020 |
November 20, 2017 |
November 21, 2017 |
|
- OLVG
Amsterdam, Netherlands
|
|
| 82 |
NCT03390114 |
Recruiting |
Cognitive Behavioral Therapy to Treat Insomnia in Persons With HIV Infection |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT03390114 |
1712469162 |
|
May 1, 2018 |
June 30, 2019 |
September 30, 2019 |
January 4, 2018 |
August 7, 2018 |
|
- Infectious Diseases Research Center
Indianapolis, Indiana, United States
|
|
| 83 |
NCT03098862 |
Recruiting |
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Identify genetic variation associated with risk of contracting clinical Ebola Virus Disease when directly exposed to the Ebola virus
- Identify genetic variation associated with mortality from Ebola VirusDisease
- Identify genetic variation associated with post recovery Ebola viral RNA persistence in bodily fluids
- (and 2 more...)
|
9000 |
All |
3 Years to 99 Years (Child, Adult, Older Adult) |
NCT03098862 |
999917077
17-I-N077 |
|
February 20, 2019 |
April 30, 2021 |
April 30, 2022 |
April 4, 2017 |
February 15, 2019 |
|
- PREVAIL JFK Medical Center
Monrovia, Liberia
|
|
| 84 |
NCT03388645 |
Recruiting |
Challenge Infection of Healthy Adult Volunteers With RSV A2 |
- Upper Respiratory Tract Infections
|
|
Interventional
|
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Assessment of expected and unexpected adverse events after challenge
- Detect RSV shedding in nasopharyngeal wash by FilmArray multiplex pCR assay and by quantitative RT-PCR and quantitative viral culture after challenge with RSV A2
- Calculate the number participants with mild to moderate upper respiratory illness after challenge, based on stdy definition of RSV illness and determine the no. of days RSV illness persists after challenge and degree of illness based on stdy def...
- (and 2 more...)
|
75 |
All |
18 Years to 50 Years (Adult) |
NCT03388645 |
180039
18-I-0039 |
|
February 20, 2018 |
November 15, 2019 |
November 15, 2020 |
January 3, 2018 |
January 15, 2019 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 85 |
NCT03239899 |
Recruiting |
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection |
|
|
Interventional
|
Phase 1 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The primary goal of the study is to determine the safety of a single dose of pembrolizumab in HIV-positive patients.
- To determine the effect of pembrolizumab on HIV-specific T-cell responses.
- To determine the effect of pembrolizumab on CSF PD-1 expression.
- To examine if pembrolizumab changes the CSF expression of HIV-specific antibody responses or CSF cytokine profiles.
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03239899 |
170145
17-N-0145 |
|
April 9, 2018 |
December 31, 2019 |
December 31, 2020 |
August 4, 2017 |
January 3, 2019 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 86 |
NCT03568383 |
Not yet recruiting |
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients |
|
- Drug: Delamanid (DLM)
- Drug: Isoniazid (INH)
- Dietary Supplement: Pyridoxine (vitamin B6)
|
Interventional
|
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percent of participants with confirmed or probable active TB at any time between Day 0 and the week 96 study visit
- Percent of participants who permanently discontinue randomized study drug (DLM or INH) due to a treatment-related adverse event
- Percent of participants with confirmed active MDR-TB at any time between Day 0 and the week 96 study visit
- (and 3 more...)
|
5610 |
All |
Child, Adult, Older Adult |
NCT03568383 |
A5300B/I2003B/PHOENIx
12041 |
PHOENIx MDR-TB |
March 15, 2019 |
December 22, 2024 |
December 22, 2024 |
June 25, 2018 |
January 29, 2019 |
|
|
|
| 87 |
NCT02262819 |
Recruiting |
Human Immunity Against Staphylococcus Aureus Skin Infection |
- Staphylococcus Aureus Skin Infection
|
|
Interventional
|
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Evaluate the local in vivo skin immune response to bacteria.
- Evaluate the keratinocyte responses to bacterial challenge.
- Determine if abnormalities in specific immune pathways, such as IL-17 and vitamin D metabolism, are present in subjects with recognized susceptibility to S. aureus infections.
- (and 3 more...)
|
300 |
All |
2 Years to 65 Years (Child, Adult, Older Adult) |
NCT02262819 |
140199
14-I-0199 |
|
October 10, 2014 |
January 1, 2025 |
January 1, 2025 |
October 13, 2014 |
January 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 88 |
NCT01200953 |
Recruiting |
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases |
- Occupational Accidents
- Incubation Period, Infectious Disese
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
|
200 |
All |
2 Years to 99 Years (Child, Adult, Older Adult) |
NCT01200953 |
100197
10-I-0197 |
|
August 4, 2011 |
|
|
September 14, 2010 |
February 1, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 89 |
NCT00789009 |
Recruiting |
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection |
- HIV Infections
- AIDS
- Opportunistic Infections
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
600 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT00789009 |
090030
09-I-0030 |
|
December 1, 2008 |
|
|
November 11, 2008 |
February 11, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 90 |
NCT00018044 |
Recruiting |
Study of Mycobacterial Infections |
- Atypical Mycobacterium Infections
- Cystic Fibrosis
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Children's National Health System
- University of Miami
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
|
|
800 |
All |
Child, Adult, Older Adult |
NCT00018044 |
010202
01-I-0202 |
|
June 27, 2001 |
|
|
June 29, 2001 |
January 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 91 |
NCT03122288 |
Recruiting |
Individualized Cognitive Training in HIV |
- HIV-Associated Cognitive Motor Complex
- Aging
- Cognitive Impairment
- (and 5 more...)
|
- Behavioral: Individualized Cognitive Training
- Other: No-Contact Control
|
Interventional
|
Not Applicable |
- University of Alabama at Birmingham
- National Institute of Nursing Research (NINR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prevalence and Severity of HIV-Associated Neurocognitive Disorder (HAND) as Measured by Neurocognitive Tests Interpreted by the Frascati Criteria
- Improvement on Everyday Functioning as Measured by the Timed Instrumental Activities of Daily Living Test
- Improvement on Everyday Functioning as Measured by the Medication Adherence Scale
- (and 5 more...)
|
146 |
All |
40 Years and older (Adult, Older Adult) |
NCT03122288 |
F161122002
1R21NR016632-01 |
TOPS |
July 27, 2017 |
December 1, 2018 |
June 30, 2019 |
April 20, 2017 |
February 7, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 92 |
NCT03662022 |
Not yet recruiting |
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar |
|
|
Interventional
|
Phase 3 |
- Institute of Tropical Medicine, Belgium
- Damien Foundation
- Centre d’Infectiologie Charles Mérieux
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Compare effectiveness in curbing transmission of leprosy of three different approaches of post exposure prophylaxis
- Assess cost and feasibility of SDDR-PEP under program conditions
- Identify patterns of clustering in transmission of leprosy, allowing better targeting of control measures
- (and 2 more...)
|
144000 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT03662022 |
1248/18 |
PEOPLE |
January 2, 2019 |
September 30, 2022 |
September 30, 2022 |
September 7, 2018 |
September 7, 2018 |
|
- Damien Foundation
Anjouan, Comoros - Damien Foundation
Mohéli, Comoros - Fondation Raoul Follereau
Miandrivazo, Menabe, Madagascar
|
|
| 93 |
NCT03385473 |
Recruiting |
Individualized Antiretroviral Therapy |
- Pharmacogenetics
- HIV
- Drug Monitoring
|
- Genetic: Pharmacogenomic index
- Diagnostic Test: Therapeutic drug monitoring
|
Interventional
|
Not Applicable |
- Hospital Italiano de Buenos Aires
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Feasibility of implementation of a multicenter study to analyze pharmacological adequation and therapeutic drug monitoring of efavirenz or atazanavir in the initial antiretroviral treatment of naive patients with HIV infection
- Frequency of adverse events
- Efficacy of antiretroviral treatment
- Cost/effectiveness compared in both arms
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03385473 |
1901 |
IAT |
October 5, 2017 |
December 15, 2019 |
December 31, 2019 |
December 28, 2017 |
December 28, 2017 |
|
- Hospital Italiano de Buenos Aires - Infectious Diseases Section
Buenos Aires, Caba, Argentina
|
|
| 94 |
NCT03751514 |
Recruiting |
Bordetella Pertussis Colonisation Challenge Study |
|
- Biological: Bordetella Pertussis B1917
- Drug: Azithromycin 500 mg
- Other: Sterile Saline
|
Interventional
|
Not Applicable |
- University of Southampton
- Public Health England
- University Hospital Southampton NHS Foundation Trust
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Phase A - Inoculum Dose Determination
- Phase A and B - Immune Responses to exposure to Bordetella pertussis
- Phase A - Accuracy of Inoculum Dosing Evaluation
- (and 9 more...)
|
80 |
All |
18 Years to 45 Years (Adult) |
NCT03751514 |
RHM MED1396
17/SC/0006 |
Periscope |
May 22, 2017 |
February 2, 2021 |
February 2, 2021 |
November 22, 2018 |
November 22, 2018 |
|
- NIHR Wellcome Trust Clinical Research Facility, Southampton General Hospital
Southampton, Hampshire, United Kingdom
|
|
| 95 |
NCT03220464 |
Recruiting |
Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT |
- Tuberculosis, Pulmonary
- Latent Tuberculosis
|
- Radiation: Ultra low dose chest computed tomography (ULDCT)
- Radiation: Chest X-ray
- Diagnostic Test: Interferon-gamma Release Assay (IGRA)
|
Interventional
|
Not Applicable |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Incidence of active pulmonary tuberculosis
- Prevalence of active pulmonary tuberculosis at enrollment
- Prevalence of latent tuberculosis at enrollment
- Change of ultra low dose chest CT findings in latent tuberculosis patients
|
116 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03220464 |
1704-157-849 |
|
June 20, 2017 |
April 30, 2019 |
April 30, 2020 |
July 18, 2017 |
July 21, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
|
| 96 |
NCT03813069 |
Recruiting
New |
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma |
|
- Other: IR3535
- Other: Permethrin lower dose
- Other: Permethrin higher dose
|
Interventional
|
Phase 2 |
- London School of Hygiene and Tropical Medicine
- Federal Minstry of Health of Ethiopia
- Oromia Regional Health Bureau, Ethiopia
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Protective Efficacy (PE)
- Complete Protection Time (CPT)
|
103 |
All |
3 Years to 65 Years (Child, Adult, Older Adult) |
NCT03813069 |
2018-kep-132 |
|
January 2019 |
April 2019 |
April 2019 |
January 23, 2019 |
January 23, 2019 |
|
- Fred Hollows Foundation
Addis Ababa, Ethiopia - London School of Hygiene and Tropical Medicine
London, United Kingdom
|
|
| 97 |
NCT02878200 |
Recruiting |
RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission |
|
- Biological: dihydroartemisinin-piperaquine
|
Interventional
|
Not Applicable |
- London School of Hygiene and Tropical Medicine
- Institute of Tropical Medicine, Belgium
- University of Sheffield
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- prevalence of malaria infection
- prevalence of clinical (laboratory confirmed) malaria cases
- the prevalence of antimalarial drug resistance molecular markers
- treatment coverage
|
8000 |
All |
6 Months and older (Child, Adult, Older Adult) |
NCT02878200 |
SCC1488 |
RHOST |
November 4, 2016 |
March 2019 |
September 2019 |
August 25, 2016 |
January 29, 2019 |
|
- Health Centres in NBR
Farafenni, North Bank Region, Gambia
|
|
| 98 |
NCT00342589 |
Recruiting |
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collection of Pneumocystis samples for laboratory studies.
|
1500 |
All |
3 Years to 99 Years (Child, Adult, Older Adult) |
NCT00342589 |
990084
99-I-0084 |
|
April 10, 1999 |
|
|
June 21, 2006 |
January 21, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 99 |
NCT02794181 |
Recruiting |
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD) |
- Zika Virus
- Dengue Virus
- Chikungunya Virus Infections
|
|
Observational
|
|
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among travel-deferred adult blood donors in the study population.
- Prevalence of ZIKV infection (RNApositives) among adult blood donors with a history of potential sexual exposure to ZIKV infection, in the study population.
- 24-week Natural History of ZIKV, DENV and CHIKV (RNA-positives).
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02794181 |
160124
16-CC-0124 |
|
June 8, 2016 |
March 31, 2019 |
March 31, 2019 |
June 9, 2016 |
August 9, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 100 |
NCT03577470 |
Recruiting |
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate |
- Human Immunodeficiency Virus (HIV)
|
- Drug: D/C/F/TAF Fixed-Dose Combination (FDC)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants with Virological Response at Week 48
- Participant's Previous Antiretroviral (ARV) Treatment History Determined Using the Web-Based Electronic Case Report Form (eCRF)
- Time to Virosuppression
- (and 12 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT03577470 |
CR108466
TMC114FD1HTX4011 |
DIAMANTE |
June 13, 2018 |
March 30, 2020 |
March 31, 2020 |
July 4, 2018 |
January 23, 2019 |
|
- Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy - Policlinico Sant'Orsola Malpighi
Bologna, Italy - Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy - (and 16 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: